NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown
Clinical Trials
3 trialsNCT00597116 2016-10-10
An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
Sanofi
Phase 2 Terminated
NCT00601614 2014-03-10
Vandetanib and Temozolomide in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery
Mayo Clinic
Phase 1 Withdrawn